Business · 15/05/2024Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to Day One Biopharmaceuticals for Rare Pediatric Disease Product OJEMDA (tovorafenib)
Summary
The FDA has awarded a priority review voucher to Day One Biopharmaceuticals, Inc. for its rare pediatric disease product OJEMDA (tovorafenib), which was approved on April 23, 2024, and meets the criteria set by the Federal Food, Drug, and Cosmetic Act.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →